Oregon Medicaid targets expensive hepatitis drug

by Jonathan J. Cooper

(AP)—An Oregon Medicaid committee is expected to significantly scale back access to an effective—but expensive—new drug used to treat hepatitis C.

The decision on Thursday would allow only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi.

Medical experts on Oregon's pharmaceutical review committee question whether the drug is worth the . Oregon's guidelines would allow the drug to be used only for patients with later stages of who have been compliant with previous medical treatments and drug-free for at least six months. The drug could only be prescribed by a liver specialist.

Oregon is grappling with the issue a day after Illinois' Medicaid program put in place tight restrictions on the use of the drug.

Related Stories

Medical groups question price of new hep C drug

date Mar 11, 2014

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

FDA advisers unanimously back J&J hepatitis C drug

date Oct 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

Recommended for you

Teva to lift bid for Mylan: report

date 7 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

date 12 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.